Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.…
Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
Edesa Biotech (NASDAQ: EDSA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 2.000 USD on 20 November 2026, up 11.7% over 52 weeks. Its 52-week range is 0.7200 USD to 20.32 USD: the price is 90.2% below the high and 177.8% above the low.
Its market capitalisation is 27.02M USD.
Edesa Biotech reports return on equity of -57.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 10.33M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.